Longevity, a relatively new investment category, had a breakthrough year in 2021, attracting more than $40 billion globally, a figure projected to grow to $600 billion by 2025. While research funding has traditionally targeted chronic diseases such as Type 2 diabetes, cardiovascular diseases, and Alzheimer’s, where risk increases with age, the field of aging science is focused on how we might prevent these chronic conditions in the first place. Longevity companies are leveraging emerging research on the underlying mechanisms of aging to develop products that extend health to match increased lifespans. With the current fragmentation and competition in this field, this invitation-only event will highlight the opportunities and challenges of investing in scientific longevity solutions, and identify where investment capital could accelerate progress and ensure access for the greatest number.

Moderators

Raj Ahuja

Associate Director, Center for the Future of Aging, Milken Institute

Paul Irving

Senior Fellow and Founding Chairman, Center for the Future of Aging, Milken Institute

Speakers

Alexandra Bause

Co-Founder and Head of Venture, Apollo Health Ventures

Kristen Fortney

CEO, BioAge Labs

Eric Verdin

President and CEO, Buck Institute for Research on Aging